Ona Therapeutics
Startup · Series BRaised $86.6M · Series B · Jun 20264 backers: Fund+, Ysios Capital, Asabys Partners+1
$86.6MTotal raised
Lately:4 news stories in 90 daysFollow changes →
Facts
as of Nov 21, 2026First-in-class ADCs tailored to attack advanced cancer.. Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer.
- Founded
- 2019
- Employees
- 51-200estimated range
- Website
- ona-therapeutics.com
These are the key facts about Ona Therapeutics on Alion as of Nov 21, 2026. It was founded in 2019. The latest round is Series B of $86.6M, announced in 2026.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
Funding
Full ledger, 1 record →Ona Therapeutics has $86.6M paid in by investors, lenders and donors.
$86.6MPaid in
Money innewest first
$86.6MPaid
Money by yearUSD, rounds and grants
Every row links its own source. A flow two sources state counts once; a figure a source does not state reads "not stated".
Milestones
Raised a round Series B $86.6M
Jun 3
Founded
2019
Newsroom
Newsmarkets.businessinsider.com
Sep 24
Sources: the outlets named on each headline, each story once
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
